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Elucidation of prion protein (PrP) functions is crucial to fully understand prion diseases. A
major approach to studying PrP functions is the use of PrP gene-knockout (Prnp−/−) mice.
So far, six types of Prnp−/− mice have been generated, demonstrating the promiscuous
functions of PrP. Recently, other PrP family members, such as Doppel and Shadoo,
have been found. However, information obtained from comparative studies of structural
and functional analyses of these PrP family proteins do not fully reveal PrP functions.
Recently, varieties of Prnp−/− cell lines established from Prnp−/− mice have contributed
to the analysis of PrP functions. In this mini-review, we focus on Prnp−/− cell lines and
summarize currently available Prnp−/− cell lines and their characterizations. In addition, we
introduce the recent advances in the methodology of cell line generation with knockout or
knockdown of the PrP gene. We also discuss how these cell lines have provided valuable
insights into PrP functions and show future perspectives.
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INTRODUCTION
Prion diseases, also called transmissible spongiform
encephalopathies (TSE), are a group of neurodegenerative
disorders that affect both humans and animals (Prusiner, 1998).
Examples of these disorders in humans include Creutzfeldt-Jakob
disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS),
kuru and fatal familial insomnia (FFI). TSEs found in animals
include scrapie, bovine spongiform encephalopathy (BSE) and
chronic wasting disease (CWD). The representative charac-
teristics of prion diseases are spongiform changes, which are
associated with neuronal loss, vacuolation, astrocytosis, forma-
tion of amyloid plaques and a failure to induce an inflammatory
response (Sakudo and Ikuta, 2009a,b). A common characteristic
of prion diseases is rapid symptom progression after a prolonged
incubation period. The damaged region of the brain differs
among each prion disease and determines the clinical signs and
symptoms of the specific disease. Although the incidence of prion
diseases is rare, it is fatal because of a lack of effective treatment
to either cure or delay disease progression. Furthermore, the risk
of prion transmission is a serious threat to public health due
to the high resistance of prion agents to standard sterilization
techniques (Sakudo et al., 2011a).
Prion protein (PrP) is the most important factor for prion
infection. This finding has been verified by experiments using
PrP gene (Prnp)-knockout (Prnp−/−) mice and cells derived from
these mice (Sakudo et al., 2006, 2007a,b). The first important
finding was that Prnp−/− mice are resistant to infection with
prion agents (Bueler et al., 1993; Prusiner et al., 1993; Manson
et al., 1994a,b). Secondly, Prnp−/− primary culture neurons
are not killed by the toxicity of prion agents or PrP(106-126)
(Brandner et al., 1996a; Giese et al., 1998). Thirdly, prions cannot
proliferate in the brain of Prnp−/− mice (Brandner et al., 1996b).
Therefore, it is apparent that PrP plays an important role in the
mechanisms of infection and contributes to the pathogenesis of
prion diseases. This is also consistent with the notion that the
conversion of cellular PrP (PrPC) into abnormal PrP (PrPSc) con-
stitutes a fundamental feature of prion diseases (Prusiner, 1998).
It seems that PrPC acts as a cellular receptor of PrPSc. Because
PrPC is thought to function as a dimeric form (Meyer et al., 2000;
Kaimann et al., 2008), PrPC-PrPSc interaction might alternate
between PrPC-PrPSc and PrPSc-PrPSc after prion infection. As
shown above, Prnp−/− mice and the derived cells have confirmed
the importance of PrP in the pathogenicity of prion diseases and
have greatly contributed to the understanding of these disorders.
However, despite the numerous studies on Prnp−/− mice, the
biological functions of PrPC, which are crucial for understanding
prion diseases, remain elusive. Cell lines are useful for detailed
analysis of gene function. Therefore, to investigate PrPC func-
tions in detail, Prnp−/− cell lines derived from Prnp−/− mice
have been established. The present review will summarize cur-
rently available Prnp−/− cell lines. In addition, recent advances in
strategies for producing cell lines in which Prnp is knocked out
or knocked down will be presented. Valuable insights into PrPC
functions made possible by the availability of these cell lines will
be introduced as well.
THE ANALYSIS OF Prnp−/− MICE FOR UNDERSTANDING
PrPC FUNCTION
One approach to studying protein function is to analyze the effect
of knocking out the corresponding gene. In the case of PrPC,
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Prnp−/− mice have been widely used for this purpose. Therefore,
studies using Prnp−/− mice should be mentioned before we
discuss Prnp−/− cell lines. Prnp−/− mice have been used for
elucidating the functions of PrPC via analysis of the phenotype
of Prnp−/− mice (Weissmann and Flechsig, 2003). Six lines of
Prnp−/− mice, designated Zrch I (Bueler et al., 1992), Zrch II
(Rossi et al., 2001), Npu (Manson et al., 1994a), Ngsk (Sakaguchi
et al., 1996), Rcm0 (Moore et al., 1999) and Rikn (Yokoyama et al.,
2001), have been generated (Figure 1). However, there were some
discrepancies among the phenotypes of the knockout mice. The
first and second knockout lines, Zrch I and Npu, were generated
by disrupting the PrP coding region located in exon 3 of the Prnp
(Bueler et al., 1992; Manson et al., 1994a). Studies on these lines
did not show any severe abnormality. Subsequently, Ngsk, Rikn,
Rcm0, and Zrch II mouse lines were generated in which the entire
coding region and part of intron 2 was deleted (Sakaguchi et al.,
1996; Moore et al., 1999; Rossi et al., 2001; Yokoyama et al., 2001).
Because of the structure of the targeted Prnp allele, intergenic
splicing between Prnp and the surrounding gene led to ectopic
expression of the surrounding gene in the brains of these mice.
This prompted the discovery of the gene Prnd located 16 kbp
downstream of Prnp, encoding the prion-related protein Doppel
(Dpl) (Moore et al., 1999), which shares ∼25% identity with
two-thirds of the C-terminal region of PrP. Ectopic expression
FIGURE 1 | Knockout constructs of type-1 and type-2 of prion protein
gene (Prnp)-knockout (Prnp−/−) mice. Structures of the constructs used
to produce six lines of Prnp−/− mice. The Prnp−/− mice are divided into
type-1 and type-2 Prnp−/− mice depending on whether the splicing
acceptor of exon 3 is disrupted. The disruption of exon 3 is correlated with
the development of late-onset ataxia and Purkinje cell loss, which is
induced by ectopic expression of Doppel (Dpl) in the central nervous
system (CNS). The structure of wild-type (WT) Prnp exon 3 and prion
protein (PrP) coding region (green box) is shown at the top. The selection
markers are indicated by orange boxes. The presence and absence of the
exon 3 splicing acceptor (SA) is correlated with the development of
late-onset ataxia. The selection markers were PGK, mouse
phosphoglycerate kinase promoter; NEO, neomycin phosphotransferase;
HPRT, mouse hypoxanthine phosphoribosyltransferase; TK, human herpes
simplex virus type 1 thymidine kinase promoter; MT, mouse
metallothionein promoter; loxP, a 34-bp recombination site from phage P1.
of Dpl leads to the development of late-onset ataxia in Prnp−/−
mice. Therefore, the ataxic phenotype of some lines of Prnp−/−
mice (Ngsk, Rikn, Rcm0, ZrchII) is due to ectopic expression of
Dpl (derived from Prnp/Prnd chimeric mRNAs through inter-
genic splicing) as a result of the disruption of the splicing acceptor
of Prnp exon 3 (Moore et al., 1999; Li et al., 2000a; Rossi et al.,
2001). In this review article, to discriminate between Prnp−/−
mice with and without ectopic expression of Dpl, we term the for-
mer ataxic Prnp−/− mice (Ngsk, Rikn, Rcm0, Zrch II) as type 2,
while the latter non-ataxic Prnp−/− mice (Zrch I, Npu) as type-1
(Figure 1).
The type-1 Prnp−/− mice display no major abnormalities.
Indeed, only small abnormalities could be found in type-1
Prnp-knockout mice. These include deficits related to neuronal
and other cellular functions such as abnormal learning and
sleep patterns, olfactory deficits, susceptibility to seizures, abnor-
mal neuromuscular function and depressive disorder as well
as abnormal glucose tolerance and deficits related to protec-
tion against pathophysiological stress (e.g., abnormal inflam-
matory responses, decreased protection against viral bacterial
infection, accelerated symptoms of experimental autoimmune
encephalomyelitis (EAE) and susceptibility to ischemic brain
injury (Onodera et al., 2014). In addition, the most consistent
phenotype of Prnp−/− mice is myelin degeneration (Nishida
et al., 1999; Baumann et al., 2007; Bremer et al., 2010). Some
of these abnormalities may be due to the genetic background
(Steele et al., 2007). Therefore, experiments using backcrossed
mice should be performed to confirm whether the observed phe-
notypes are attributable to PrP. There are also possibilities of
synergistic phenotypes in a combination of mouse strain genetic
backgrounds and knockout constructs. In addition, the breeding
condition of the mice may affect emergence of some pheno-
types. For knockout mouse studies, confirmation of findings
using mice with distinct knockout constructs and genetic back-
grounds in an independent laboratory will be required to firmly
establish conclusions regarding PrP function. Indeed, we have
recently reviewed the topic of different Prnp−/− mouse pheno-
types to assess the physiological function of PrPC (Onodera et al.,
2014).
PrP FAMILY PROTEINS AND THEIR KNOCKOUT MICE
Recently, new members of the PrP family of proteins have been
identified; namely, Dpl, encoded by Prnd, and Shadoo (Sho),
encoded by Sprn. These PrP family proteins are all subject
to endoproteolytic processing (Mays et al., 2014) and local-
ize to similar membrane environments (Li et al., 2013). Dpl
and Sho pose interesting and important questions concerning
PrP function. Given that the function of PrP remains elusive,
information obtained from comparative structural and func-
tional studies of these PrP family proteins are of great interest.
Specifically, complementary, overlapping or interference of func-
tion among PrP family members might be found from these
analyses.
There are reports indicating functional interaction between
PrP and Dpl. It has been shown that the ataxic phenotype
observed in type-2 Prnp−/− mice can be neutralized by cross-
ing the mice with those overexpressing wild-type mouse PrP
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(Nishida et al., 1999; Rossi et al., 2001). These findings suggest
that PrP has a neuroprotective role and functionally interacts
with Dpl. Another report showed that the toxicity of Dpl over-
expression in mice and cells is inhibited by PrP expression. In
a separate report, using immortalized Prnp−/− neuronal cells, a
decrease of cellular copper levels brought about by serum depri-
vation was also inhibited by PrP. However, the inhibitory effect
of PrP on decreased copper levels was prevented by Dpl over-
expression (Sakudo et al., 2004). A further study demonstrated
that endoproteolysis of PrP was affected by Dpl overexpression in
Prnp−/− cells (Sakudo and Onodera, 2011b). Therefore, PrP-Dpl
interaction functions both in vitro and in vivo.
Dpl is localized in the brain for only a limited duration in
the developmental process (Li et al., 2000b), whereas analysis
of Prnd−/− mice showed that Dpl deficiency did not inter-
fere with embryonic and postnatal development (Behrens et al.,
2002; Genoud et al., 2003). Dpl was produced at a late stage of
spermatogenesis. Spermatids of Prnd−/− mice were reduced in
numbers, immobile, malformed and unable to fertilize oocytes,
resulting in male sterility. PrP is also expressed in testis, but unlike
other cells the PrP is expressed as N-terminally truncated iso-
forms (Peoc’h et al., 2002) or a C-terminally truncated isoform
(Shaked et al., 1999). The C-terminal region of PrP resembles Dpl,
suggesting that these proteins share a common function in testis
in the case of N-terminally truncated PrP (Peoc’h et al., 2002)
or show a complementary function to each other in the case of
C-terminally truncated PrP (Shaked et al., 1999). Currently, there
is no evidence that Dpl is associated with the pathogenesis of
prion diseases. For example, the level of Dpl expression does not
correlate with the onset of prion disease (Weissmann and Aguzzi,
1999; Tuzi et al., 2002).
By contrast, there is evidence that Sho is implicated in prion
diseases. For example, the expression of Sho decreases with the
accumulation of PrPSc after prion infection (Watts et al., 2007a,
2011). Sho protein levels were decreased in the brains of Prnpa
and Prnpb mice (Westaway et al., 2011), hamsters, meadow, voles
and sheep infected with natural and experimental prion strains
(Watts et al., 2011). In addition, time course experiments showed
that the levels of PrPSc vs. Sho protein were inversely proportional
(Watts et al., 2011). Membrane anchoring and the N-terminal
domain of PrP both influenced the inverse relationship between
PrPSc and Sho (Watts et al., 2011). By contrast, increased expres-
sion of Sho did not influence prion replication (Watts et al.,
2011), suggesting Sho merely acts as a marker for prion disease.
Therefore, it remains unclear how Sho contributes to the patho-
genesis of prion diseases. Indeed, depletion of Sho appears to
be unimportant in terms of triggering prion diseases and in the
processing and degradation of PrPSc.
In terms of physiological action, Sho can exhibit neuroprotec-
tive properties similar to PrPC (Watts andWestaway, 2007b;Watts
et al., 2007a) and share a number of binding partners common
with PrPC (Watts et al., 2009). In addition, as Sho has a similar
structure to the N-terminal region of PrP (Watts and Westaway,
2007b), the relationships between the structural similarity and
functional similarity of PrP and Sho are interesting. Sprn−/− mice
underwent a subtle alteration of body weight (Passet et al., 2013),
which was not noted in the case of double-knockout (Sprn and
Prnp) mice. In addition, Prnp/Sprn knockout mice survived to
over 600 days of age without any severe abnormality, suggest-
ing the existence of a discrete signaling pathway of Prnp and
Sprn to maintain neuronal survival. Sho was also found to be
expressed in the trophoblast cells of the placenta (Passet et al.,
2012). Comparative transcriptomic analyses performed between
E6.5 and E7.5 Sprn-knockdown (using RNAi) embryo and their
wild-type counterparts suggested that Sho has functions comple-
mentary, not necessary overlapping, with those of PrP, associated
with cellular movement and hematological system development
and differentiation (Passet et al., 2012). Interestingly, the expres-
sion profile of Sprn in testis and ovary resemble that of Prnp.
Thus, interaction among three PrP family members may play
important roles in reproductive tissues. Although the contri-
bution of PrP family members to embryogenesis is suggested,
Prnp/Sprn knockout mice are healthy and fertile (Daude and
Westaway, 2012a; Daude et al., 2012b). Therefore, further studies
on reproductive tissues are required to resolve the apparent dis-
crepancy in the data. The topic of Sho is also discussed in detail
in a review article in this research topic (Makzhami et al., 2014).
As mentioned above, analysis of the phenotypes of knockout mice
and comparison of PrP family members does not fully elucidate
the functions of PrP. Therefore, other approaches to analyze PrP
function are required. Next, we discuss the use of Prnp−/− cell
lines to study the role of PrP.
CHALLENGES TO INVESTIGATING PrPC FUNCTIONS IN
VITRO
Cells have been classified into approximately 200 different types
(Obinata, 2007). Through development and maintenance dur-
ing adult life, cells are differentiated and obtain characteristics
to elicit specialized functions. Differentiation can be chemically
induced by various stimuli such as growth factors, cytokines,
and hormones (Alberts et al., 2008). Histological location of
the cells also influences cell differentiation. In order to study
each cell type possessing a specialized function, the cells need
to be separated from each other. Examination of large, pure
populations of specific cell types is extremely valuable in advanc-
ing our understanding of the cells. Primary cultures are com-
posed of a heterogeneous cell population and can be maintained
only for a limited period of time. Although PrPC is highly
expressed in neurons, primary neuron cultures can be main-
tained for just a few weeks. Moreover, cells belonging to a rare
cell type are often difficult to isolate and culture. For detailed
functional gene analysis, an efficient transfection procedure is
required. However, the transfection efficiency of primary cul-
tures is generally low, especially when using primary neurons.
If gene transfer to a primary culture of neurons or other cell
types with low efficiency is necessary, a viral vector is required
for the introduction of inducible genes. In this respect, cell lines
are useful for detailed analysis of gene function because the
transfection efficiency is usually high compared to that of pri-
mary cultures. In addition, cell lines can be maintained almost
indefinitely.
However, studying pure cell lines has the disadvantage that it
can only reflect a cell-autonomous condition, whereas biological
processes in an organism involve a heterogeneous cell population.
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Co-cultures of multiple cell populations may help to mimic the
heterogeneous condition. Additionally, because there are a lot of
cell types in an organism, it is very difficult to match cell types
between cell lines when a comparison is required. Thus, compar-
isons between a wild-type and a knockout cell line are suboptimal
for analyzing a target gene. Alternatively, a cloned knockout cell
line should be compared in the absence and presence of the target
gene.
PrPC EXPRESSION AND PrPC-INTERACTING PROTEINS
PrPC is expressed in a variety of tissues. Northern blot analysis
has shown that the levels of PrP mRNA vary among tissues, with
the highest levels found in the brain and placenta; moderate lev-
els in the testis, heart, and lung; and lower levels in the spleen
and kidney (Horiuchi et al., 1995; Saeki et al., 1996). In sheep,
3–5μg PrPC/g of tissue is present in the brain, whereas the level
of PrPC per gram of tissue is 100 ng in the heart and skeletal mus-
cle, 200 ng in the lung, 40 ng in the spleen, and 3 ng in the liver
(Moudjou et al., 2001). Thus, the quantity of PrPC in the brain
is 20- to 50-fold higher than in the other tissues. This observa-
tion suggests that PrPC plays an important role in several tissues,
particularly in the brain.
Recently, it has been shown that PrPC binds a variety of partner
molecules. Using radioisotope or enzyme-labeled PrP, interaction
of PrP with glial fibrillary acidic protein (GFAP), a NF-E2 related
factor 2 (Nrf2), amyloid precursor protein 1 (Aplp1), F-box
protein-6, neural F-box protein 42 kDa (NFB42), postsynaptic
density 95 kDa (PSD-95)/ SAP-90 associated protein, protein
tyrosine phosphatase non-receptor type-21, and predicted pro-
tein KIAA0443 was reported (Yehiely et al., 1997). A two hybrid
system showed that laminin (Graner et al., 2000), 37-kDa/67-
kDa laminin receptor (Gauczynski et al., 2001), 37-kDa laminin
receptor precursor (Rieger et al., 1997), heat shock protein 60 kDa
(Hsp60) (Edenhofer et al., 1996) and Bcl-2 (Kurschner and
Morgan, 1995) all bind PrP. Co-immunoprecipitation experi-
ments were used to identify PrP-interacting molecules, which
included prion interactor 1 (Pint1) (Spielhaupter and Schatzl,
2001), synapsin Ib (Spielhaupter and Schatzl, 2001), growth
factor receptor-bound protein 2 (Grb2) (Spielhaupter and
Schatzl, 2001), and neurotrophin receptor interacting MAGE
(melanoma-associated antigens) homolog (NRAGE) (Bragason
and Palsdottir, 2005), dystroglycan (Keshet et al., 2000), the neu-
ronal isoform of nitric oxide synthase (nNOS) (Keshet et al.,
2000), glucose regulated protein 94 (Grp94) (Capellari et al.,
1999), protein disulphide isomerase (Capellari et al., 1999), cal-
nexin (Capellari et al., 1999), calreticulin (Capellari et al., 1999)
and zeta-associated protein-70 (ZAP-70) (Mattei et al., 2004).
A cross-linking method demonstrated interaction of PrP with
tubulin (Nieznanski et al., 2005) and neural adhesion molecule
(N-CAM) (Schmitt-Ulms et al., 2001). Complementary hydropa-
thy and pull-down assays were able to show the interaction of PrP
with stress inducible protein 1 (STI1) (Martins et al., 1997) and
Hsp60 of Brucella abortus (Watarai et al., 2003). Intriguingly, PrP
interacts with caveolin-1 (Toni et al., 2006), while cross-linking
of cell-surface PrP stimulated caveolin-1-dependent interaction
with Fyn tyrosine kinase (Mouillet-Richard et al., 2000), result-
ing in neurite outgrowth and differentiation of neuronal cells
(Mouillet-Richard et al., 2000; Pantera et al., 2009). Thus, PrP
contributes to the control of the cellular redox state and home-
ostasis of neuronal cells (Mouillet-Richard et al., 2007). Because
Fyn is involved in various signaling pathways, the interaction
implies that PrPC has diverse functions. Most interestingly, a
wealth of recent studies has established that PrP interacts with
Amyloid β protein (Aβ), which is generated by the abnormal pro-
cessing of the amyloid precursor protein (APP) by β-secretase,
β-site APP cleaving enzyme (BACE1) and involved in the patho-
genesis of Alzheimer’s disease (Larson et al., 2012; Um et al.,
2012; Um and Strittmatter, 2013; Dohler et al., 2014). In addi-
tion, several reports have shown that PrPC interacts with APP
(Yehiely et al., 1997; Kaiser et al., 2012). Several reports have
further demonstrated an involvement of PrP in the toxicity of
Aβ, although the use of different in vitro or transgenic mod-
els has yielded contrasting results (Schwarze-Eicker et al., 2005;
Laurén et al., 2009; Balducci et al., 2010; Calella et al., 2010;
Chung et al., 2010; Kessels et al., 2010; Morales et al., 2010;
Ordóñez-Gutiérrez et al., 2013; Gasperini and Legname, 2014).
Some groups have also reported that Fyn kinase mediates sig-
nal transduction downstream of the PrPC-Aβ complex (Larson
et al., 2012; Um et al., 2012; Um and Strittmatter, 2013). Because
PrPC inhibits BACE1 either by direct interaction (Griffiths et al.,
2011) or indirectly without interaction (Parkin et al., 2007;
McHugh et al., 2012), reduction of the PrPC level may increase
Aβ. Therefore, PrPC may be involved in the pathogenesis of
Alzheimer’s disease not only by transducing Aβ toxic signals but
also via regulation of neurotoxic Aβ production. Taken together,
most of the interacting proteins are important factors involved
in survival, proliferation, differentiation, development, and stress
response. However, it should be mentioned that this interaction
may depend on the specific cell type and/or the surrounding
tissue environment.
Currently, Prnp−/− cell lines have predominantly been estab-
lished from brain as well as fibroblast and macrophage cell lines
(Figure 2). Next, we will introduce the Prnp−/− cell lines estab-
lished so far.
FIGURE 2 | Types of Prnp−/− cell lines that are available. Currently
available Prnp−/− cell lines can be divided into four types i.e., neuronal cells
(HpL3-4, Zpl2-1, NpL2, F14), astroglial cells (GpL1), macrophage/microglia
(MpLZ, MG0), and fibroblasts (SFK-B, SFK-C, PrP0/0/1).
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HpL, Prnp−/− NEURONAL CELL LINES
To gain further insights into PrP functions, cell lines (HpL and
HW)were established using the gene transfer of oncogenes by our
group (Kuwahara et al., 1999). HpL was the first Prnp−/− cell line,
while HW is the wild-type counterpart. These cell lines were from
the hippocampal area of Rikn Prnp−/− mice and Prnp+/+ mice
using a target for infection with a recombinant retrovirus vec-
tor containing the simian virus 40 (SV40) T-antigen gene (Ryder
et al., 1990). The virus vector was used for transfection of ψ2
packaging cells, which are stable cells containing all of the struc-
tural retroviral protein genes (gag, pol, and env). The retrovirus
particles produced from the transfected ψ2 packaging cells were
used for immortalization by introduction of the SV40 large T
antigen gene. The hippocampal primary cultures derived from
Prnp−/− and Prnp+/+ mice were infected with the above retro-
virus, then incubated, selected, expanded and finally subjected to
limiting dilution to obtain cloned cell lines. Three Prnp−/− cell
lines, HpL2-1, HpL-3-2 and HpL3-4, and 3 Prnp+/+ cell lines
HW8, HW9, HW19, were thereby obtained (Kuwahara et al.,
1999).
The HpL and HW cells were exposed to dibutyl cyclic AMP
(dcAMP) at 0.4–6mM, retinoic acid (RA) at 0.1–10μM, and
phorbol 12-myristate 13-acetate (PMA) at 160–1600 nM, for up
to 10 days of culture. These compounds all induced morpho-
logical changes, i.e., elongation of neurite-like processes, in both
HpL and HW cells. Among the tested compounds, the morpho-
logical change was best observed by stimulating the HpL and
HW cells in medium with dcAMP or PMA without fetal calf
serum (FCS). To further characterize the cell types of the cell
lines, reverse transcription polymerase chain reaction (RT-PCR)
was applied to monitor the expression of neurofilament genes.
Treatment with PMA resulted in the amplification of the pre-
dicted size products corresponding to neurofilament (NF)-68K
and NF-200K genes. The NF-68K gene was transcribed in all
3 HpL and 3 HW cell lines with or without PMA treatment.
After treatment with PMA, the NF-200K gene was transcribed
in all three HW cell lines and in only one of the HpL cell lines
(HpL2-1). The transcription of GFAP, a glial cell marker, was not
detected in HpL or HW cells. Taken together, the results suggest
that all six of these cell lines belong to the neuronal precursor cell
lineage.
Next, the characteristics of HpL cells were compared to those
of HW cells. The most remarkable feature of HpL cells by com-
parison to HW cells was observed when the serum was removed
from the culture medium (Kuwahara et al., 1999). Serum depriva-
tion caused comparable morphological changes within 1 h in all
cell lines whether or not they were treated with dcAMP. However,
within 4 days the HpL cells had died in the serum-free culture.
The process started by the rounding up of the cells, cytoplas-
mic condensation and neurite retraction. By contrast, all three
HW cell lines maintained their structural integrity under the
same culture conditions. DNA fragmentation, a characteristic of
apoptosis, was firstly observed at 12 h and peaked at 24 h after
serum deprivation in the HpL cells, whether or not they were
treated with PMA or cAMP. However, no such DNA fragmenta-
tion was detected in any of the HW cells after serum deprivation.
Cultured cells in serum-free medium for 6, 12, or 24 h were
ethanol-fixed and stained with propidium iodide before analy-
sis by flow cytometry (Sakudo et al., 2003a). A significant peak
in the fluorescence low-intensity area (hypodiploid cells), which
corresponds to the fraction of apoptotic cells, was detected only
in the samples from HpL cells at 6, 12, and 24 h after serum
withdrawal. Because HpL3-4 cells started to generate superoxide
anion at 6 h after serum deprivation, superoxide anion genera-
tion seems to induce apoptosis of the HpL3-4 cells (Sakudo et al.,
2003b). To investigate whether the abnormality observed in HpL
cells was due to the absence of PrP, the HpL cell lines (HpL2-1 and
HpL3-4) were transfected with PrP expression vector. Cells trans-
fected with PrP-expressing vector, designated HpL2-1TR and
HpL3-4TR, survived under serum-free conditions (Kuwahara
et al., 1999). In contrast, HpL2-1 and HpL3-4 cells transfected
with empty vector showed apoptotic features similar to those of
HpL2-1 and HpL3-4 cells under serum-free conditions. These
results suggest that HpL cells are susceptible to serum deprivation
and that apoptotic cell death is suppressed by reintroduction of
Prnp. Moreover, levels of superoxide anion generated fromHpL3-
4 cells after serum deprivation were suppressed by reintroduction
of Prnp (Sakudo et al., 2003b). Therefore, these results suggest
that PrP functions by displaying anti-oxidative and anti-apoptotic
activity. Recent studies have shown that the anti-apoptotic activity
of PrP is species specific, as indicated by evidence that apopto-
sis was suppressed by mouse PrP but not by bovine or hamster
PrP (Wu et al., 2008). Moreover, as serum-free supernatants of
HW cell cultures could not rescue the HpL cells from apoptosis,
molecules secreted fromHW cells do not appear to be involved in
the neuroprotective mechanism of PrP (Kuwahara et al., 1999).
In addition to the cell death, HpL cell lines show significantly
shorter neurite extension in comparison with HW cell lines after
treatment with PMA, suggesting that PrP is involved not only in
survival but also in differentiation (Kuwahara et al., 1999).
Recently, in addition to our group, several other groups have
independently confirmed the neuroprotective function of PrP
using the above-mentioned PrP-deficient cell lines or other cell
lines. Kim et al. reproduced our findings using HpL3-4 cells,
and detected significantly greater changes in the calcium ion
level, transmembrane potential and cytochrome c level in the
mitochondria of HpL3-4 cells over those observed in Prnp-
reintroduced HpL3-4 cells after serum deprivation (Kim et al.,
2004). Mange et al. also confirmed that cell viability was increased
by the reintroduction of Prnp into HpL3-4 cells (Mange et al.,
2004). By contrast, Christensen et al. confirmed a moderate but
significant cytoprotective effect of PrP in serum-deprived HpL3-
4 cells, but concluded the degree of neuroprotection offered
by PrP was either not physiologically relevant or that the cell
culture systems cannot adequately model the situation in vivo
(Christensen and Harris, 2008). However, we believe the HpL3-4
cells used in these experiments were not appropriate for this
analysis because they did not express neuronal markers (i.e., neu-
ronal nuclear antigen (NeuN), microtubule-associated protein 2
(MAP2) or NF-L) (Christensen and Harris, 2008). This opin-
ion is also supported by the evidence that Prnp-Prnd chimeric
mRNA transcribed from the Prnp promoter was not detected
by RT-PCR and immunofluorescence analysis in the cells used
by Christensen et al. By contrast, our results were confirmed by
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Prnp-Prnd chimeric mRNA expression in HpL3-4 cells (Sakudo
et al., 2005b).
HpL3-4 cells are susceptible to various forms of stress. For
example, Vassallo et al. showed HpL3-4 cells are prone to cell
death induced by 3-morpholinosydnonimine (SIN-1) (Vassallo
et al., 2005). Vassallo et al. further investigated the signal cas-
cade of apoptosis induced by serum deprivation and SIN-1, and
showed that recruitment of phosphatidylinositol 3-kinase by PrP
contributes to cellular survival under conditions of oxidative
stress imposed by SIN-1 or serum deprivation in HpL3-4 cells.
Prnp-transfected HpL3-4 cells show autophagy after amyloid β
treatment. Amyloid β1−42 (Aβ42) enhanced autophagic flux, such
as the formation of autophagic vacuoles, was observed in HpL3-
4 cells in which Prnp was reintroduced. However, autophagy
was impaired in HpL3-4 cells transfected with empty vector
(Nah et al., 2013). In addition, PrP-dependent recruitment of
Beclin1 (BECN1) into lipid rafts was observed in the HpL3-4
cell line. Because BECN1 is associated with phosphatidylinositol
3-kinase catalytic subunit type 3 (PIK3C3), there will be recruit-
ment of BECN1-PIK3C3 complex into the lipid raft, which is
an essential step for autophagy. The observed autophagy could
be due to interaction of PrP and BECN1. Therefore, stud-
ies using HpL3-4 cells revealed that PrP is involved in Aβ42
induced autophagy.
HpL3-4 cells were also susceptible to a monomeric, highly
α-helical form of PrP known as toxic PrP (Zhou et al., 2012).
Toxic PrP was identified as a recombinant form of PrP that
was subjected to denaturation, fractionation and dilution refold-
ing. However, there is no information on the comparative effect
of toxic PrP on PrP-expressing and non-expressing HpL3-4
cells. Similarly, in another report, although treatment with Aβ42
showed a cytotoxic effect and increased levels of reactive oxygen
species (ROS) in HpL3-4 cells, there was no comparison with
the HpL3-4 counterpart in which Prnp was reintroduced (Hyeon
et al., 2012).
It has also been reported that treatment of HpL3-4 cells with
hydrogen peroxide increases intracellular calcium levels in a PrP
expression dependent manner, suggesting PrP functions as a sen-
sor of hydrogen peroxide (Krebs et al., 2007). Therefore, it appears
that PrPC plays an important role in anti-oxidative stress. As such,
the signaling cascade and oxidative metabolism were investigated
in HpL3-4 cells after serum deprivation (Sakudo et al., 2003a,b).
The studies revealed decreased expression of anti-apoptotic pro-
teins Bcl-2 and Bcl-xL in HpL3-4 cells during apoptosis induced
by serum deprivation. Suppression of apoptosis by overexpression
of Bcl-2 and Bcl-xL, suggested that cell death in this model sys-
tem is apoptotic, and Bcl-2 and Bcl-xL play important roles in the
apoptosis of HpL3-4 cells (Sakudo et al., 2003a). Furthermore,
HpL3-4 cells subjected to serum deprivation showed a more
marked decrease in intracellular copper concentration, greater
increases of intracellular superoxide anion and caspase-3/9 acti-
vation, and a smaller increase in intracellular hydrogen peroxide
levels by comparison to HpL3-4 cells in which Prnp was rein-
troduced (Sakudo et al., 2003b). HpL3-4 cells also showed a
decrease of cellular superoxide dismutase (SOD) activity and cel-
lular copper content compared to HpL3-4 cells expressing PrP
(Sakudo et al., 2003b). By contrast, levels of Prnp-Prnd chimeric
mRNA and Prnd mRNA were unchanged in HpL3-4 cells after
serum deprivation (Sakudo et al., 2005c). Higher coxsackievirus
B3 and poliovirus production in HpL3-4 cells showed that PrP
may be involved not only in the inhibition of virus replication
but also anti-apoptotic functions against virus-induced apopto-
sis (Nakamura et al., 2003b; Baj et al., 2005). Taken together, our
studies of HpL cell lines have revealed that PrP plays important
roles in differentiation, proliferation and cell survival (i.e., roles
in anti-apoptosis, anti-oxidative and anti-viral effect via regulat-
ing a variety of cell signal cascades). The results obtained from
the study of HpL cell lines are consistent with those derived
from other studies using primary cultures and other cell lines,
which also showed the involvement of PrP in neuroprotection
and differentiation (Milhavet and Lehmann, 2002; Roucou et al.,
2004).
Studies using HpL cells have contributed to identifying PrP-
interacting molecules or PrP-regulated genes because HpL does
not express PrP. Moreover, Prnp-transfected HpL cells are an ideal
counterpart for PrP analysis. Zafar et al. used HpL3-4 cells in
combination with STrEP-Tactin chromatography and quadrupole
time-of-flight tandem mass spectrometry (Q-TOF MS/MS) anal-
ysis to search for PrP-interacting proteins and identified 28 new
hits (Zafar et al., 2011). Among them, Rab7a, a regulator of vesic-
ular transport located in a specific intracellular compartment
(early to late endosome) and involved in vesicle biogenesis and
vesicle fusion to lysosomes, was found to interact with PrP and
regulate PrP trafficking in HpL3-4 cells. Furthermore, 23 PrP-
interacting proteins were identified by using deletion mutants
of PrP [PrP(23-230)], which lack the N-terminal signal pep-
tide sequence and C-terminal glycosylphoshatidylinositol (GPI)
anchor site (Zafar et al., 2014). Among them, one novel protein
(pyruvate kinase isozymes M1/M2) (PKM2) was found to bind
PrP(23-230). In addition, PrP(23-230) exhibits reduced anti-
apoptotic activity against staurosporine-induced cell stress with
higher expression of PKM2 than full length PrP in HpL3-4 cells,
suggesting that PrP(23-230) regulates PKM2 and renders the
cells susceptible to stress.
Taking advantage of the absence of Prnp, HpL3-4 cells have
been used for the analysis of exogenous PrP. Hachiya et al.
reported an N-terminal PrP fragment and C-terminal frag-
ment showed distinct intracellular distribution using trans-
fection of double-labeled fluorescent PrP into HpL3-4 cells
(Hachiya et al., 2004). The N-terminal PrP fragment was asso-
ciated with microtubules and had an intracellular localiza-
tion, but did not co-localize with any intracellular organelle
markers.
OTHER Prnp−/− NEURONAL CELL LINES
As described earlier, PrP exhibits a neuroprotective effect against
apoptosis induced by serum deprivation in HpL3-4 cells, which
are derived from type-2 Prnp−/− mice (Rikn) with ectopic
Dpl expression. To investigate whether PrP inhibits apoptotic
neuronal cell death in the absence of Dpl, neuronal cell lines
were established from the brain of type-1 Prnp−/− mice (Zrch
I), which did not show ectopic Dpl expression (Nishimura
et al., 2007). The results showed that reintroduction of Prnp
potently inhibited serum-withdrawal apoptotic cell death in
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a Zrch I neuronal Prnp−/− cell line (NpL2). Moreover, PrP
expression was found to upregulate cellular SOD activity in
NpL2 cells. Therefore, we concluded that ectopic Dpl pro-
duction did not affect the anti-apoptotic and anti-oxidative
functions of PrP. Thus, it was confirmed that the presence
of PrP is directly correlated with protection against oxidative
stress.
Kim et al. established neuronal cell lines from hippocam-
pal neurons of Zrch I Prnp−/− mice by lipofection of SV40
large T antigen-expressing vector and found higher prolifera-
tion of neuronal cell lines from Prnp−/− mice (Zpl) than those
derived from Prnp+/+ mice (ZW) (Kim et al., 2005). Zpl cells
do not express Dpl because the cells are derived from type 1
Prnp−/− mice (Zrch I). Moreover, Zpl cells showed higher lev-
els of apoptosis and autophagy compared to ZW cells after serum
deprivation (Oh et al., 2008). The neuroprotective activity of PrP
in Zpl cells was confirmed by reintroduction of Prnp into Zpl
cells. Cleaved caspase-3 levels for apoptotic index and LC3-II
levels for autophagy index were correlated with the expression
of PrP. Furthermore, PrP(53-94), octapeptide repeat (OR)-
deficient PrP, did not display a protective activity in Zpl cells,
indicating the importance of the OR region in the neuroprotec-
tive activity of PrP. These results are consistent with the HpL3-4
studies using deletion PrP mutants as described in the following
section.
The F14 neuronal cell line is another Prnp−/− derived cell line,
obtained by fusion of Prnp−/− cerebellar cells and mouse neu-
roblastoma cells (Holme et al., 2003). The cells were used for
investigating the effect of PrP mutations on PrP membrane ori-
entation, although the characteristics of PrP-expressing cells and
PrP-deficient cells have not been compared.
Although not Prnp-knockout cells, Loubet et al. used the
1C11 cell line, a neuroepithelial progenitor for shRNA (short
hairpin RNA)-mediated knockdown of Prnp, to investigate the
gene silencing effect of Prnp (Loubet et al., 2012). 1C11 cells
lack neuron-associated functions and acquire, upon differenti-
ation, the functions of serotogenic or noradrenergic neuronal
cells associated with cytoskeleton remodeling along neuritogen-
esis. The results showed that Prnp knockdown caused impaired
neuronal polarization with inhibition of the initial sprouting of
neurite. Further analysis of the signaling pathway suggests that
PrPC contributes to neurite polarization by modulating integrin
interactions with the extracellular matrix.
ASTROGLIAL Prnp−/− CELL LINES
PrPC is expressed not only in neuronal cells but also in non-
neuronal cells such as glial cells. Therefore, studies on PrPC
functions using non-neuronal cell lines are necessary. To address
this issue, the Prnp−/− astroglial cell line GpL1 from hippocampal
cells of Zrch I Prnp−/− mice were established by retrovirus-
mediated SV40 large T antigen-immortalization using a retro-
virus vector employing methods described above (Nishimura
et al., 2008). GpL1 cells were confirmed to express GFAP but not
MAP-2, indicating that GpL1 is an astroglial cell line. Transfection
of Prnp suppressed cell death in GpL1 cells under serum-free
conditions. This finding is similar to the results of Prnp−/− neu-
ronal cell lines HpL3-4 and NpL2. The Prnp-transfected GpL1
cells (GpL1-PrP) showed increased SOD activity compared to
control GpL1 cells transfected with empty vector (GpL1-EM).
Thus, this study extended the notion that PrPC prevents apop-
tosis by its anti-oxidative function in not only a Prnp−/− neu-
ronal cell line but also a Prnp−/− astroglial cell line after serum
withdrawal.
In addition to PrPC function in independent cells, we have
investigated whether PrP expression on the cell surface of astroglia
influences neuronal survival because neurons and astroglia are
closely coupled in their metabolic activities (Verkhratsky et al.,
2014). Thus, the effect of PrP expression on cell viability of
NpL2 cells under co-culture with GpL1-EM or GpL1-PrP cells
in the absence of serum was investigated (Onodera and Sakudo,
unpublished results). For co-culture experiments, GpL1-EM and
GpL1-PrP cells were prepared and replaced with a serum-free
DMEM. NpL2-EM and NpL2-PrP cells were plated onto cover-
slips, which were then transferred to a dish containing GpL1-EM
or GpL1-PrP cells. After 4 days of co-culture, the coverslips were
retracted and cell viability measured. The results showed that the
NpL2 cell viability was significantly increased under co-culture
with GpL1 cells transfected with Prnp (GpL1-PrP) compared to
GpL1 cells transfected with empty vector (GpL1-EM). Similar
results were observed when we used both NpL2 cells transfected
with Prnp (NpL2-PrP) and NpL2 cells transfected with empty
vector (NpL2-EM). These findings suggest that the neuronal cell
viability depended on the PrP expression in feeder astroglia in
the co-culture system. Taken together, astroglial cell lines are
useful for revealing the mechanism of PrPC not only in indepen-
dent astroglial cells but also in the function of the neuron-glia
relationship.
MACROPHAGE/MICROGLIA Prnp−/− CELL LINES
Recent studies have shown that cells of the immune system, such
as macrophages, dendritic cells (DCs) or lymphocytes, can act as
a replication site or as a reservoir for prions (Aucouturier and
Carnaud, 2002). Follicular dendritic cells (FDCs) in the germinal
centers of lymphoid organs are reported to be sites of PrPSc accu-
mulation (Mcbride et al., 1992; Hill et al., 1999; Aucouturier and
Carnaud, 2002). Current data suggest that the prion agent might
be acquired by migratory DCs and macrophages (Maignien et al.,
2005). However, the function of PrPC in macrophages remains
unclear.
Macrophages express PrPC at a very low level. To study
PrPC functions in macrophage, the mouse bone marrow-derived
macrophages (BMM) from FVB/N Prnp+/+ and Zrch I Prnp−/−
mice were transformed with a replication-defective retrovirus
encoding SV40 large T antigen by a similar method previously
used for the establishment of HpL, NpL, and GpL cell lines (Uraki
et al., 2010). The cells were then selected and cloned. Among
the obtained clones, we used MWF3-3 (from FVB/N Prnp+/+
mice) and MplZ4-3 (from Zrch I Prnp−/− mice) for compari-
son, because these cells expressed macrophage specific proteins
(F4/80 and MOMA-2) and displayed phagocytotic properties.
Because it was previously reported that Prnp−/− neuronal HpL
and NpL cells and astroglial GpL cells are sensitive to oxida-
tive stress in serum-free conditions, MWF3-3 and MplZ4-3 cells
were subjected to serum deprivation. TheMplZ4-3 cells died after
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withdrawal of serum, whereas most MWF3-3 cells survived under
the same culture conditions. These findings suggest that PrPC
increases the survival rate of macrophages.
With regard to the characteristics of the Prnp−/− macrophage
cell line, we have analyzed their cell morphology and phago-
cytotic activity. The Prnp−/− macrophage cell line (MplZ4-3)
showed shorter pseudopodium extension and less phagocytotic
activity of latex beads than a Prnp+/+ macrophage cell line
(MWF3-3). These findings are consistent with the results using
peritoneal macrophages from Prnp−/− and Prnp+/+ mice using
latex beads (Nitta et al., 2009). However, the findings are incon-
sistent with a previous study showing that primary cultures of
Zrch I Prnp−/− macrophages have increased rates of phagocy-
tosis of zymosan particles, suggesting PrP negatively regulates
this process (De Almeida et al., 2005). One possible explanation
for this discrepancy may be the different mouse strains used in
these experiments. Whereas the previous report examined pri-
mary cells derived from C57BL/6, we used a macrophage cell
line derived from FVB/N. Similarly, Prnp−/− mice are resistant
to infection by Brucella abortus, which is supported in the report
by De Almeida et al. implying that the deletion of PrP contributes
to host defense against bacterial infection (Watarai et al., 2003).
However, this was not confirmed in the case of Brucella suis in
another laboratory (Fontes et al., 2005). In addition, a recent
report by Nuvolone et al. suggests that the increased phagocyto-
sis of apoptotic cells, which was reported as attributable to the
absence of Prnp in Prnp−/− mice, has been shown instead to be
caused by differences in a linked locus encoding signal regulatory
protein-α (Sirpa) (Nuvolone et al., 2013). Thus, further studies
would be required for investigating whether Sirpa-polymorphism
influences the responses to zymosan or phagocytosis of latex
beads.
Microglia are the primary immune cells of the central nervous
system (CNS), and are highly similar to peripheral macrophages.
These cells play important roles as the major inflammatory cell
type in the brain, and respond to pathogens and injury and con-
tribute to destroying pathogens as well as removing damaged
cells. Several studies have indicated that microglia are impli-
cated in the pathogenic events of prion diseases (Williams et al.,
1994; Brown, 2001b). However, the pathophysiological func-
tion of PrPC in microglia remains unclear. Iwamaru and Kitani
et al. obtained the MG0 Prnp−/− microglial cell line, which
is derived from the brains of Rikn Prnp−/− mice (Iwamaru
et al., 2007). To immortalize these microglial cells for estab-
lishing the MG0 cell line, c-myc-containing retroviral vector
was used. The MG0 cells were confirmed to be positive for
the microglial markers Mac-1 and F4/80 and negative for the
astroglial marker GFAP and neuronal marker MAP2. Moreover,
these cells were shown to have phagocytotic activity and to
produce inflammatory cytokines, such as tumor necrosis fac-
tor α, interleukin-1α and interleukin-6, when stimulated with
lipopolysaccharide. However, there are no reports on the compar-
ison between MG0 and the wild-type counterpart MG6 cell line
or PrP-overexpressed microglial cell line MG20. Persistent infec-
tion of scrapie and BSE in these cells has been reported. Further
analysis of PrP function in microglia using the MG0 cell line is
keenly awaited.
FIBROBLAST Prnp−/− CELL LINES
Satoh et al. established skin fibroblast Prnp−/− cell lines (SFK)
derived from continuous cultures of abdominal skin explants of
Ngsk Prnp−/− mice. SFK cells showed decreased expression of
Ras- and Rac-related proteins compared to Prnp+/+ skin fibrob-
last cell lines (SFH) (Satoh et al., 1998, 2000), while heat shock
proteins were expressed at the same level in SFK and SFH cells in
the presence and absence of heat stress (Satoh et al., 1998). Other
groups established Prnp−/− fibroblasts (PrP0/0/1 cell line) from
Ngsk Prnp−/− mice by immortalization with the chemical muta-
gen 3-methylcholanthrene (Prcina et al., 2010). The proliferation
rate of PrP0/0/1 cells expressing human PrP was lower those of
non-transfected PrP0/0/1 cells, and was negatively correlated with
the PrP expression level. However, the authors also stated that
these observations may be due to the antibiotic selection marker
on the vector.
MECHANISMS BY WHICH PrP PREVENTS APOPTOSIS IN
THE HpL CELL LINE
One way to identify the important regions of PrP is to gener-
ate partially deleted or mutated forms of PrP and transfect them
into the Prnp−/− cell line. Endogenous PrP expression in the
Prnp+/+ cell line may interfere with these experiments. Hence,
the Prnp−/− cell line is particularly useful for this approach. Here,
we introduce our studies using HpL3-4 cells for investigating the
important regions for PrP function (Figure 3).
PrP contains disulfide links (S–S), Asn-linked glycosylation
sites (CHO), a signal peptide sequence (SP) and a GPI anchor
attached to its C-terminus (Brown, 2001a). In addition, PrPC con-
tains two domains evolutionarily conserved among mammals;
viz., the OR (amino acid residue 51–90 in mouse PrP) and the
hydrophobic region (HR) (amino acid residue 112–145 in mouse
PrP) domains.
OR, which is composed of five octapeptide repeats,
P(Q/H)GGG(G/-)WGQ, is highly conserved among mam-
mals and can selectively bind copper (Hornshaw et al., 1995;
Brown et al., 1997; Miura et al., 1999; Viles et al., 1999; Kramer
et al., 2001). Zinc, manganese, and nickel also bind to PrP but
with lower affinity (Pan et al., 1992; Brown et al., 2000; Jackson
et al., 2001). The binding of metals occurs via histidine residues
located in the OR domain. The binding of copper to PrP is
thought to be indispensable for the SOD activity of PrP (Brown
et al., 1999; Cui et al., 2003). In addition, as metals such as copper
are essential for myelin formation and maintenance (Skripuletz
et al., 2008; Benetti et al., 2010), regulation of copper by PrPC
may be involved in demyelination of Prnp−/− mice (Nishida
et al., 1999; Baumann et al., 2007; Bremer et al., 2010).
HR, which contains the highly conserved sequence motif
AGAAAAGA (Gasset et al., 1992; Schatzl et al., 1995), has
been shown to be critical for PrP topology in the endoplas-
mic reticulum membrane (Hegde et al., 1998), STI1 binding
(Zanata et al., 2002) as well as normal metabolic cleavage
(Chen et al., 1995; Mange et al., 2004) such as α-cleavage and
β-cleavage.
To investigate the roles of OR and HR in the anti-apoptotic
function of PrP, several deletions within these domains of
mouse PrP or fusions with mouse PrP and Dpl have been
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FIGURE 3 | Schematic representations of PrP deletion mutants or
PrP-Dpl fusion proteins and Prnp−/− cells (HpL3-4) expressing these
mutants that undergo apoptosis under serum deprivation. Schematic
representations of deletion mutants of mouse PrP and PrP-Dpl fusion
protein are shown. Mutants of mouse PrP [PrP: wild-type PrP; #1,
PrP(53-94, Q52H); #2, PrP(95-132); #3, PrP(124-146)] were
prepared using restriction digestion/ligation. Schematic locations of the
deletions as compared with the wild-type protein are shown by a space
within the bar next to the indicated protein. Dpl lacks sequences
homologous to the octapeptide repeat (OR) and hydrophobic regions (HR)
of PrP. ORDpl [PrP(1-95)-Dpl] is Dpl fused with amino acid residues 1-95 of
PrP containing the OR. ORHRDpl [PrP(1-124)-Dpl] is Dpl fused with amino
acid residues 1-124 of PrP containing the OR and N-terminal half of HR. The
numbers refer to the amino acid residues in the mouse PrP sequence or
Dpl sequence. The Asn-linked glycosylation sites (CHO), signal peptide
sequence (SP), octapeptide repeat region (OR) and hydrophobic region (HR)
are shown. The regions forming an α-helix secondary structure are shown
as α1-α3, whereas those forming a β-sheet are shown as β1 and β2. Both
PrP and Dpl have a glycosylphosphatidylinositol (GPI) anchor attached to its
C-terminus. HpL3-4 cells expressing wild-type PrP (PrP), PrP(53-94,
Q52H) (#1), PrP(95-132) (#2), PrP(124-146) (#3), Dpl (Dpl),
PrP(1-95)-Dpl (ORDpl), PrP(1-124)-Dpl (ORHRDpl) or the empty vector alone
(EM) were serum-deprived. The rate of apoptosis of the cells after serum
deprivation for 24 h is shown on the right. The number of pluses (+)
indicates the degree of apoptosis. Minus (−) indicates a lesser degree of
apoptosis. Updated from Figure 4 in Sakudo et al. (2006) and Figure 3 in
Sakudo et al. (2007b) with permission from Bentham Science Publishers,
Ltd. and John Wiley & Sons, Inc., respectively.
made (Figure 3). The anti-apoptotic function of three PrP dele-
tion constructs and PrP-Dpl fusion constructs as well as the
control constructs was tested following stable transfection into
Prnp−/− neuronal cells HpL3-4 [HpL3-4 cells expressing wild-
type PrP (PrP: HpL3-4-PrP), PrP(53-94, Q52H) (#1: HpL3-
4-#1), PrP(95-132) (#2: HpL3-4-#2), PrP(124-146)
(#3: HpL3-4-#3), PrP(1-95)-Dpl (ORDpl: HpL3-4-ORDpl),
PrP(1-124)-Dpl (ORHRDpl: HpL3-4-ORHRDpl) or empty
vector alone (EM: HpL3-4-EM)]. Western blotting confirmed
that the cell clones expressed the deletion mutants and fusions
at similar levels to those of clones expressing the full-length pro-
tein. In the absence of serum, HpL3-4 cells undergo cell death
with features of apoptosis, whereas Prnp−/− cells transfected
with Prnp are resistant to serum deprivation (Kuwahara et al.,
1999; Sakudo et al., 2003b, 2005a). Serum deprivation showed
that the control transfectants (HpL3-4-EM) underwent rapid cell
death, while the full-length PrP-transfected cells were signifi-
cantly protected. In contrast, the cells expressing OR-deficient
PrP (HpL3-4-#1) showed higher levels of cell death compared
with HpL3-4-EM cells. Interestingly, the cells expressing the N-
terminal half of HR-deficient PrP (HpL3-4-#2) underwent cell
death at equivalent levels to HpL3-4-EM cells. In contrast, the
cells expressing the C-terminal half of HR-deficient PrP (HpL3-
4-#3) underwent cell death at equivalent levels to HpL3-4-PrP
cells. The cells expressing Dpl fused to OR (HpL3-4-ORDpl) died
at slightly higher levels compared to HpL3-4-EM cells, while the
cells expressing Dpl fused to OR and N-terminal half of HR
(HpL3-4-ORHRDpl) displayed elevated levels of survival over
HpL3-4-EM cells (Lee et al., 2006).
Therefore, the data suggest that the anti-apoptotic function
of PrPC can be regulated by not only the OR domain but also
the N-terminal half of HR. In addition, a fusion protein contain-
ing OR of PrP did not protect the cells against stress, whereas
extending the fusion to the N-terminal half of HR did provide
some protection. These findings support the notion that both the
OR and HR are important domains for PrP function. Moreover,
measurement of cellular SOD activity showed that OR and the
N-terminal half of HR are necessary for the activation of cellular
SOD in HpL3-4 cells (Sakudo et al., 2005c). Therefore, regula-
tion of the anti-oxidative defense systems, such as SOD activity,
by PrP suggests this domain contributes to the anti-oxidative
and anti-apoptotic activity during serum deprivation in HpL3-4
cells.
Mouse PrP is cleaved at the β site located in OR and near
His96 as well as the α site located at position 111/112 (Mange
et al., 2004). A PrP fragment was immunocaptured from HpL3-
4 cells expressing wild-type PrP using an antibody recognizing
the N-terminal region of PrP. This fragment mainly includes the
N-terminal portion of the protein generated after cleavage at the
β site. Interestingly, β cleavage was observed after oxidative stress
treatment in vitro (Mcmahon et al., 2001). Furthermore, HpL3-
4 cells expressing PrP(110-119) lacking the α cleavage site were
more protected against stress than those expressing an equivalent
level of wild-type PrP (Mange et al., 2004). These observations
suggest that PrP(110-119) is the dominant positive form of PrP.
Because the absence of α cleavage was found to enhance cell via-
bility, α cleavage appears to suppress the protective activity of
PrP. By contrast, β cleavage may contribute to protection. Further
studies are required to analyze the effect of β cleavage on the
neuroprotection mechanism of PrP.
Regarding OR and HR, several potential interactors of PrP
have been reported. Copper specifically binds the OR of PrP
(Hornshaw et al., 1995; Brown et al., 1997; Viles et al., 1999;
Kramer et al., 2001). STI1, binds with amino acid residues
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113-128 located in the N-terminal half of the HR of PrP (Zanata
et al., 2002). Indeed, immunoprecipitation studies suggest that
STI1 interacts with PrP in HpL3-4-PrP cells (Sakudo et al.,
2005a). Therefore, we performed additional studies using HpL3-4
cells in order to determine how STI1 and copper might contribute
to PrP-dependent anti-oxidative signaling. To investigate whether
the STI1 is important for the biological activities displayed by PrP,
the effect of the inhibitory peptides against PrP-STI1 on HpL3-4-
EM cells was compared to that on HpL3-4-PrP cells under serum-
free conditions (Sakudo et al., 2005a). The inhibitory peptides
are toxic to HpL3-4-PrP cells due to inhibiting the SOD activity,
although this is not the case for HpL3-4-EM cells (Sakudo et al.,
2005a). Regarding copper, the cellular copper concentration was
decreased in HpL3-4-EM cells, but not in HpL3-4-PrP cells under
serum deprivation (Sakudo et al., 2004). Therefore, it is proposed
that STI1 and copper might be involved in PrP-dependent SOD
activation that can inhibit apoptosis via the OR and N-terminal
half of PrP.
By considering the data reported using HpL cell lines, it is
further proposed that the susceptibility of HpL3-4 cells to cell
death is probably due to reduced SOD activity, induced, at least
in part, by the absence of PrP-STI1 signals and the abnormality
of copper homeostasis as well as the lack of β cleavage. Taken
together, these findings suggest that PrP plays an anti-oxidative
role and functions only under extreme stress such as oxidative
conditions.
CONCLUSIONS AND FUTURE PERSPECTIVES
The list of abnormalities caused by PrP-deficiency from the results
of phenotype analysis of Prnp−/− mice and from comparison
between PrP-non-expressing cells and PrP-expressing cells con-
tinues to grow. Nonetheless, there has been little consensus from
these studies regarding the overall main cellular function of
PrPC. To enable us to analyse PrPC in detail, Prnp−/− cell lines
have been established. Recently, the number of available Prnp−/−
cell lines has increased, including neuronal cells, astroglial cells,
microglia, macrophages, and fibroblasts (Table 1). Rescue of Prnp
by reintroducing into Prnp−/− cell lines will provide convinc-
ing data. If further evidence is required, genetic complementation
using the PrP transgene should be performed using a vector
driven Prnp promoter. Indeed, PrPC function may differ depend-
ing on its expression level. As a consequence, levels of PrPC
expression that are either too high or too low may mask the true
biological function of the protein. Indeed, overexpression may
cause the emergence of different functions from the real physi-
ological function. Thus, if possible, analysis should be performed
using physiological expression levels of PrPC in each cell type.
However, in the case of low PrPC expressing cells, it becomes very
difficult to detect the PrPC expression and analyse PrPC function
(Raeber et al., 1999; Prinz et al., 2004).
The use of the Prnp−/− cell lines has facilitated the identifica-
tion of abnormalities caused by PrP-deficiency at the cellular level
(Table 2). Establishment of more Prnp−/− cell lines will further
contribute to our understanding of PrPC function. For exam-
ple, PrP family members are known to be expressed in repro-
ductive tissues, such as testis, ovary, and placenta (Bonnet and
Pailhoux, 2014; Makzhami et al., 2014). Thus, cells derived from
reproductive tissues should also be used for the establishment of
Prnp−/− cell lines. The importance of PrPC in leukocyte func-
tion has also been suggested because Prnp−/− lymphocytes show
a reduction of mitogen response, cytokine production and pro-
liferation (Kubosaki et al., 2003; Bainbridge and Walker, 2005).
Recent studies have also demonstrated that PrPC plays a role
in T cell and dendritic cell interactions (Ballerini et al., 2006).
Therefore, the establishment of a Prnp−/− leukocyte cell line
would be interesting.
As knockout animals lack all PrP expression, it is unclear
whether the alteration and phenotypes in Prnp−/− mice are
attributable to defects in cell function or development. Function
of PrPC in the maturation process is feasible (Martin-Lannerée
et al., 2014). Recent developments in regenerative medicine
enable us to use various stem cells, such as embryonic stem (ES)
cells and induced pluripotent stem (iPS) cells (Yamanaka, 2007).
Establishment of Prnp−/− ES or iPS cells would open the oppor-
tunity for detailed analysis of PrPC function in reprogramming,
expansion, isolation and differentiation.
Themost studied phenotype of Prnp−/− mice is myelin degen-
eration. This phenotype is seen in both type 1 and type 2 Prnp−/−
mice (Nishida et al., 1999; Baumann et al., 2007; Bremer et al.,
2010). The myelin degeneration phenotype is caused by a defi-
ciency of PrPC, suggesting that myelin maintenance may be a
representative physiological function of PrPC. The process of
demyelination is usually related to an abnormality of the immune
system (Ramesh et al., 2013). The abnormal activity of immune
cells may cause demyelination. Indeed, defects of immune cells in
Prnp−/− mice have been reported in several papers.Myelin sheath
is composed of Schwann cells and oligodendrocytes (Alberts et al.,
2008). As Schwann cell and oligodendroglia is one of glial cells,
the study using glial Prnp−/− cell line GpL1might reveal some
characteristics of PrPC related to myelin maintenance.
If knockout of Prnp is not required, suppression of Prnp
is relatively easily achieved by gene silencing technology using
siRNA (small interference RNA), miRNA (micro-RNA), bi-
shRNA (bifunctional short hairpin RNA), or shRNA (Kubowicz
et al., 2013). Indeed, shRNA of Prnp has been used for producing
PrPC-depleted 1C11 neuroectodermal cells (Loubet et al., 2012).
If a knockout of Prnp is required, the relevant Prnp−/− cell line
should be generated (Figure 4). Recent development of immor-
talization techniques enables cells derived from Prnp−/− mice to
be immortalized using oncogene transfection, radiation, fusion
with cancer cells or treatment with chemical mutagens. In other
cases, cells derived from transgenic mice with an oncogene (e.g.,
temperature sensitive SV40 largeT or p53) that is overexpressed,
mutated or deleted can proliferate and be maintained in culture
medium, resulting in the establishment of a cell line (Obinata,
2007). Alternatively, gene editing techniques such as CRISPR
(Clustered Regularly Interspaced Short Palindromic Repeat)
(Hsu et al., 2014), ZFN (Zinc Finger Nuclease) (Swarthout
et al., 2011) or TALEN (Transcription activator-like effec-
tor nuclease) (Wright et al., 2014) can be used to knockout
Prnp, resulting in the production of Prnp+/− or Prnp−/− cell
lines.
Prnp−/− cell lines are mainly used for two experimental
purposes; analysis of PrPC function and the study of prions.
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Table 1 | Prnp−/− cell lines and their characteristics.
Names Method of production
of cell lines
Cell type Prnp−/−
mouse origin
Culture medium Main characterization
compared to PrP
expressing cells
References
HpL2-1,
HpL3-2,
HpL4-3
Retrovirus-mediated
method by SV40 large T
antigen expressing
vector
Neuronal-precursor
cells (expessing NF-
68K)
Rikn 10% FCS-DMEM Susceptible to serum
deprivation
Kuwahara et al.,
1999
Zpl2-1,
Zpl2-4,
Zpl3-4
Lipofection of SV40 large
T antigen expressing
vector
Neuronal cells
(expressing NeuN)
ZrchI DMEM Higher prolifertion rate Kim et al., 2005
SFK-B,
SFK-C
Continuous culture of
abdominal skin explants
Skin fibroblast cells Ngsk 10% FCS-DMEM Decreased expression of
Ras and Rac related
proteins
Satoh et al.,
1998, 2000
F14 Fusion of PrP-knockout
cerebellar cells and
mouse neuroblastoma
cells
Neuronal cells
(expressing NeuN,
MAP-2, and
synaptophysin)
Npu Serum containing
DMEM
Similar distribution of
GFP-PrP fusion protein
Holme et al.,
2003
NpL2 Retrovirus-mediated
method by SV40 large T
antigen expressing
vector
Neuronal cells
(expressing NF-L,
NF-M, NF-H, and
MAP-2)
ZrchI 10% FCS-NB/B27
medium
Susceptible to serum
deprivation
Nishimura et al.,
2007
MG0 Retrovirus-mediated
method by c-myc
expressing vector
Microglial cell
(expressing Mac-1
and F4/80)
Rikn 10% FCS-DMEM
supplemented with
100μM
β-mercaptoethanol,
10μg/ml insulin
Comparison has not
been performed
Iwamaru et al.,
2007
MpLZ4-3 Retrovirus-mediated
method by SV40 large T
antigen expressing
vector
Macrophage
(expressing
MOMA-2 and F4/80)
ZrchI 10% FCS-DMEM Shorter pseudopodium
extension and less
phagocytotic activity
Uraki et al., 2010
PrP0/0/1 Treatment with chemical
mutagen
(3-methylcholanthrene)
Embryonic fibroblast
(expressing
fibronectin)
Ngsk 10% FCS-MEMD
supplemented with
2mM-glutamine
Higher prolifertion rate
(probably artificial)
Prcina et al.,
2010
GpL1 Retrovirus-mediated
method by SV40 large T
antigen expressing
vector
Glial cells
(expressing GFAP)
ZrchI 10% FCS-DMEM Susceptible to serum
deprivation
Nishimura et al.,
2008
DMEM, Dulbecco’s modified Eagle’s medium.
MCA, Methylcholanthrene, which is a highly carcinogenic polycyclic aromatic hydrocarbon produced by burning organic compounds at very high temperatures.
NB/B27 medium, neurobasal medium (NB) (Gibco BRL, Gaithersburg, MD, USA) supplemented with B27 supplement (B27) (Gibco) and glutamine.
Updated from Table 3 in Sakudo et al. (2006) with permission from Bentham Science Publishers, Ltd.
For example, there are several reports of the successful pro-
duction of monoclonal and polyclonal antibodies against PrP
by immunizing Prnp−/− mice with recombinant murine PrP
(Zanusso et al., 1998), human recombinant PrP folded into α
or β (Beringue et al., 2003), purified PrPC and PrPSc (Prusiner
et al., 1993; Tayebi et al., 2011), scrapie-infected mouse neurob-
lastoma cells (Nakamura et al., 2003a), DNA plasmids encoding
Prnp (Krasemann et al., 1996a,b), PrP-displaying retrovirus par-
ticles (Nikles et al., 2005), and PrP-coated microbeads (Tayebi
et al., 2011). Thus, by immunizing Prnp−/− mice with the derived
Prnp−/− cell lines transfected with Prnp or mutated Prnp, spe-
cific antibodies to wild-type or mutated PrP could be readily
obtained. Furthermore, to obtain specific antibodies to PrPSc,
immunization of Prnp−/− mice with prion-infected Prnp−/−
cells transfected with Prnp could be a promising approach.
There is a species barrier in prion susceptibility, which is
determined by the difference between the species of the host
expressing PrP and species of prion agent (Beringue et al., 2008).
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Table 2 | Abnormality of PrP gene-deficient cell lines.
Names Main characterization compared to PrP expressing cells References
HpL2-1, HpL3-2,
HpL4-3
Higher rate of apoptosis by serum deprivation Kuwahara et al., 1999; Sakudo et al., 2003a, 2005a,b,c;
Kim et al., 2004; Vassallo et al., 2005; Wu et al., 2008
HpL3-4 Decrease of intracellular copper concentration after serum
deprivation
Sakudo et al., 2004
HpL3-4 Decrease of cellular SOD activity Sakudo et al., 2003a
HpL3-4 Bigger increase of intracellular superoxide anion after serum
deprivation
Sakudo et al., 2003a
HpL3-4 Reduced increase of intracellular hydrogen peroxide after serum
deprivation
Sakudo et al., 2003a
HpL3-4 Bigger increase of caspase-3/9 activation after serum deprivation Sakudo et al., 2003a
HpL3-4 Increased sensitivity of poliovirus infection Baj et al., 2005
HpL3-4 Increased coxsackievirus B3 production and apoptotic cell death Nakamura et al., 2003a
HpL3-4 Alteration of Ca2+ concentration in mitochondria after serum
deprivation
Kim et al., 2004
HpL3-4 Alteration of transmembrane potentials in mitochondria after serum
deprivation
Kim et al., 2004
HpL3-4 Alteration of cytochrome c level in mitochondria after serum
deprivation
Kim et al., 2004
HpL3-4 Higher rate of apoptosis by SIN-1 Vassallo et al., 2005
HpL3-4 Reduced PI 3-kinase activity Vassallo et al., 2005
HpL3-4 Decrease of cellular viability Mange et al., 2004; Christensen and Harris, 2008
HpL3-4 Shorter neurite extension after differentiation Kuwahara et al., 1999
HpL3-4 Suceptible to amyloid beta toxicity and amyloid beta-inducing
autophagy
Nah et al., 2013
HpL3-4 Decreased rise in intracellular calcium following hydrogen peroxide
treatment
Krebs et al., 2007
HpL3-4 Neutralization of Dpl toxicity Sakudo et al., 2005c
NpL2 Decrease of SOD activity Nishimura et al., 2007
NpL2 Higher rate of apoptosis by serum deprivation Nishimura et al., 2007
Zpl2-1, Zpl2-4, Zpl3-4 Higher prolifertion rate Kim et al., 2005
Zpl3-4 Increased autophagy induced by serum deprivation Oh et al., 2008
Zpl3-4 Higher rate of apoptosis and autophagy by serum deprivation Oh et al., 2008
GpL1 Decrease of SOD activity Nishimura et al., 2008
GpL1 Higher rate of apoptosis by serum deprivation Nishimura et al., 2008
GpL1 Decrease of cellular viability of co-cultured neuronal cells Onodera and Sakudo, unpublished results
MplZ3-4 Shorter pseudopedium extension and reduced phagocytotic activity Uraki et al., 2010
PrP0/0/1 Higher proliferation rate (may be non-specific) Prcina et al., 2010
SFK-B, SFK-C Decreased expression of Ras and Rac related proteins Satoh et al., 1998, 2000
PI3, phosphatidylinositol 3.
SIN-1, 3-morpholinosydnonimine.
SOD, superoxide dismutase.
Updated from Table 4 in Sakudo et al. (2006) with permission from Bentham Science Publishers, Ltd.
Prnp−/− cell lines are useful for producing susceptible cells to
target species of prion agent after Prnp transfection of the tar-
get species. Importantly, endogenous PrP is not present in the
Prnp−/− cell line. Thus, interference by endogenous PrP does not
occur in a Prnp−/− cell line. The Prnp−/− cell line transfected
with deletion mutants of PrP can be used for investigating impor-
tant regions of PrP for prion infection. Previous results using the
HpL3-4 cell line and chandler scrapie strain showed that OR is an
essential region for the production of PrPSc during the early stage
of infection (Sakudo et al., 2008). This was supported by other
reports using the HpL3-4 cell line and 22L scrapie strain, indi-
cating that substitution of amino acid residues of mouse PrP at
position 96, located in the region between OR and HR, decreased
PrPSc formation (Maas et al., 2007). The report also showed
that the C-terminal half of PrP impacts on conversion efficiency.
The C-terminal half of PrP includes regions forming a secondary
structure of α-helix, termed α1-α3, while that of β-sheet is termed
β1 and β2. Substitution of amino acid residues of mouse PrP at
position 132 (located between β1 and α1), 150 (α1 region), 167
(located between β2 and α2), 189 (α2 region) and 204 (α3 region)
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FIGURE 4 | Strategies for obtaining cell lines in which Prnp is
suppressed or knocked out. Established Prnp−/− cell lines can be
obtained from a number of distributors. If suppression of Prnp is required,
rather than a knockout of Prnp, gene silencing technology using siRNA
(small interference RNA), miRNA (micro-RNA) bi-shRNA (bifunctional short
hairpin RNA) or shRNA (short hairpin RNA) is applicable. In other cases,
when a new Prnp−/− cell line is generated, immortalization of cells derived
from Prnp−/− mice is usually performed. Alternatively, gene editing
techniques such as CRISPR (Clustered Regularly Interspaced Short
Palindromic Repeat), ZFN (Zinc Finger Nuclease), or TALEN (Transcription
activator-like effector nuclease) can be used to knockout Prnp, resulting in
the production of Prnp+/− or Prnp−/− cell lines. Cells can be immortalized
using oncogene transfection, radiation, fusion with cancer cells, or
treatment with chemical mutagens. In other cases, cells derived from
transgenic mice with an oncogene (e.g., temperature sensitive SV40
(Simian virus 40) large T, p53 etc.) that is overexpressed, mutated or
deleted can proliferate and be maintained in culture medium. Continuous
fibroblast culture can also be used. A cell line may be established after
cloning and selection of these cells.
abolished the efficient conversion of PrPSc. Taken together, these
results suggest OR, α-helices and the surrounding region con-
tributes to the susceptibility of prion infection. Newly generated
PrPC and PrPSc antibodies together with cell lines that are sus-
ceptible or non-susceptible to target species of prion agents will
be extremely useful for exploring prion biology.
Finally, we would like to emphasize that development
of “OMICS” such as genomics, epigenomics, proteomics,
metabolomics and transcriptomics will enable us to obtain a
global view of the network of processes that are regulated by PrPC.
By exploiting the combination of Prnp−/− cell lines, comparison
of PrP-expressing and PrP-non-expressing cells by OMICS will
provide invaluable information on the effect of PrP-deficiency
and fundamental differences caused by PrP-deficiency. The accu-
mulated knowledge using these systems will be of great help in
understanding PrPC functions, which is also important in terms
of clarifying the etiology of prion diseases.
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